January 9, 2012
The new UC San Diego-Roche Extending Innovation Network (EIN) program has been launched with selection of its first three research projects at the University of California, San Diego School of Medicine.
January 22, 2014
Scientists at the University of California, San Diego have developed a new genetic platform that allows efficient production of naturally occurring molecules, and have used it to produce a novel antibiotic compound. Their study, published this week in PNAS, may open new avenues for natural product discoveries and drug development.
December 5, 2013
…antibiotics and developing new drugs against bacteria already resistant to conventional drug treatments. But understanding how bacteria grow and evolve drug resistance could also help stop its spread by allowing scientists to target the process of evolution itself. “Understanding how bacteria harboring antibiotic resistance grow in the presence of antibiotics…
May 6, 2024
Researchers from University of California San Diego have developed a new AI tool to that generate new drug candidates for cancer, which could help streamline the typically laborious drug discovery process.
January 31, 2023
UC San Diego scientists developed an artificial intelligence tool that could accelerate the development of new high affinity antibody drugs.
September 13, 2018
…identified three new molecular drug targets in Naegleria fowleri and a number of drugs that are able to inhibit the amoeba’s growth in a laboratory dish. Several of these drugs are already approved by the U.S. Food and Drug Administration for other uses, such as antifungal agents, the breast cancer…
November 14, 2011
…have identified a new drug discovery approach enabling the destruction of the most highly proliferative tumors. The discovery, published in the November 13 online issue of the journal Nature Medicine, points to an effective, alternative method for killing fast-growing cancer cells without causing some of the negative effects of current…
September 25, 2012
Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.
October 9, 2014
…unreleased proprietary data for drug discovery through a new $3.7 million effort funded by the National Institutes for Health. The project, which is led by UC San Diego principal investigators Rommie Amaro, Victoria Feher and Dr. Michael K. Gilson, includes a major subcontract to Rutgers University, directed by Dr. Stephen…
March 19, 2012
Chemists at the University of California, San Diego have produced the first high resolution structure of a molecule that when attached to the genetic material of the hepatitis C virus prevents it from reproducing. Hepatitis C is a chronic infectious disease that affects some 170 million people worldwide and causes…
